EUVIMEDEUVIMED entdecken
Crossref

Liraglutide promotes osteogenic differentiation of mesenchymal stem cells by inhibiting M1 macrophage polarization and CXCL9 release in vitro

Yilin He, Wenpeng Song, Yinxin Deng, Xiao Lin, Zhenhua Gao, Pan Ma

Molecular and Cellular Endocrinology · 2025

DOI: 10.1016/j.mce.2024.112441 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular and Cellular Endocrinology, 2025. Verfasst von Yilin He und 5 weiteren Autor:innen. Beteiligte Einrichtung: Implant Department, Beijing Stomatological Hospital, School of Stomatology, Capital Medical University, Tiantan Xili No.4, Dongcheng District, Beijin…. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Liraglutide, Osteogenesis, Cell Differentiation. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As a GLP-1 receptor agonist widely used in treating type 2 diabetes, liraglutide shows potential applications in bone tissue engineering. This study investigated liraglutide's direct effects on rat bone marrow mesenchymal stem cells (BMSCs) osteogenic differentiation and its regulatory mechanism through macrophage polarization. Results showed that liraglutide significantly enhanced BMSC migration and osteogenic differentiation. Additionally, liraglutide markedly inhibited M1 macrophage polarization induced by LPS and IFN-γ, reducing inflammatory factors CXCL9 and TNF-α secretion, possibly by partially reversing M1 macrophage regulatory signals (AMPK and NF-κB pathways). Compared to M1 macrophage-conditioned medium (M1-CM), conditioned medium from liraglutide-treated macrophages showed stronger promotion of BMSC osteogenic differentiation, though this effect was reversed by CXCL9 addition. The study demonstrates that liraglutide enhances BMSC osteogenic capacity both directly and by inhibiting M1 macrophage polarization and CXCL9 secretion, offering a new therapeutic option for severe bone defects with inflammatory responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesenchymal Stem CellsLiraglutideOsteogenesisCell DifferentiationChemokine CXCL9MacrophagesCell PolarityAnimalsRatsCell MovementRats, Sprague-DawleyCulture Media, ConditionedNF-kappa BSignal TransductionLipopolysaccharidesCells, CulturedMale

Stichwörter der Autor:innen

Bone regenerationCXCL9LiraglutideMacrophage polarization

Substanzen

LiraglutideChemokine CXCL9Culture Media, ConditionedNF-kappa BLipopolysaccharides

Autor:innen und Institutionen

  • Implant Department, Beijing Stomatological Hospital, School of Stomatology, Capital Medical University, Tiantan Xili No.4, Dongcheng District, Beijing, 100050, China.
  • Department of Stomatology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
  • Department of Stomatology, Beijing Hospital of Integrated Traditional Chinese and Western Medicine, Beijing, 100039, China.
  • Implant Department, Beijing Stomatological Hospital, School of Stomatology, Capital Medical University, Tiantan Xili No.4, Dongcheng District, Beijing, 100050, China. Electronic address: zhenhua_gao@ccmu.edu.cn.
  • Implant Department, Beijing Stomatological Hospital, School of Stomatology, Capital Medical University, Tiantan Xili No.4, Dongcheng District, Beijing, 100050, China. Electronic address: mapanxw@163.com.

Zitieren

APA

He, Y., Song, W., Deng, Y., Lin, X., Gao, Z., & Ma, P. (2025). Liraglutide promotes osteogenic differentiation of mesenchymal stem cells by inhibiting M1 macrophage polarization and CXCL9 release in vitro. Molecular and Cellular Endocrinology. https://doi.org/10.1016/j.mce.2024.112441

Vancouver

He Y, Song W, Deng Y, Lin X, Gao Z, Ma P. Liraglutide promotes osteogenic differentiation of mesenchymal stem cells by inhibiting M1 macrophage polarization and CXCL9 release in vitro. Molecular and Cellular Endocrinology. 2025. doi:10.1016/j.mce.2024.112441

BibTeX
@article{He2025,
  author = {He, Yilin and Song, Wenpeng and Deng, Yinxin and Lin, Xiao and Gao, Zhenhua and Ma, Pan},
  title = {Liraglutide promotes osteogenic differentiation of mesenchymal stem cells by inhibiting M1 macrophage polarization and CXCL9 release in vitro},
  journal = {Molecular and Cellular Endocrinology},
  year = {2025},
  doi = {10.1016/j.mce.2024.112441}
}
Kostenlos starten →